Stéphane Culine

5PUBLICATIONS

65CO-AUTHORS

ChemotherapyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (5)

Sort by Publication Date:

|Jun 02, 2026

Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer.

|May 04, 2023

Short-course treatment after complete response to pembrolizumab in metastatic urothelial bladder cancer: a case series.

Henri Plais, Clément Dumont, Hélène Gauthier

|Mar 29, 2023

Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial.

Stéphane Culine, Valentin Harter, Clémentine Krucker

|Mar 05, 2022

Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.

Joaquim Bellmunt, Ronald de Wit, Yves Fradet

|Mar 17, 2021

Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium.

Jörg Beyer, Laurence Collette, Nicolas Sauvé

Pageof 1

Frequent Collaborators

Cora N Sternberg

Andrea Necchi

Jörg Beyer

Laurence Collette

Nicolas Sauvé

Gedske Daugaard

Darren R Feldman

Alexey Tryakin

Xin Gao

Ugo De Giorgi

Frequent Collaborators

Cora N Sternberg

Andrea Necchi

Jörg Beyer

Laurence Collette